Serotonin toxicity:
a practical approach to diagnosis and treatment

Geoffrey K Isbister, Nicholas A Buckley and Ian M Whyte

With the introduction of numerous serotonergic agents in the past two decades, serotonin toxicity has become an important and common adverse drug effect, which can be mild, moderate or even life-threatening. Serotonin toxicity can occur from an overdose, drug interaction or adverse drug effect involving serotonergic agents. Selective serotonin reuptake inhibitors (SSRIs) are one of the commonest groups of drugs taken in overdose, and serotonin toxicity occurs in 15% of SSRi overdoses. A growing list of medications has been associated with serotonergic toxicity; the drugs that have been clearly associated are given in Box 1. The potential for the development of serotonin toxicity is particularly important in patients being prescribed psychotropic medications, with an increasing proportion of the population taking the newer antidepressants.

Serotonin toxicity results from an excess of serotonin (5-hydroxytryptamine [5-HT]) in the central nervous system (CNS), which can be due to several different pharmacological mechanisms. These include inhibition of the metabolism of serotonin (monoamine oxidase inhibitors), prevention of the reuptake of serotonin in nerve terminals (serotonin reuptake inhibitors), and increased serotonin precursors (tryptophan) or serotonin release (serotonin-releasing agents) (Box 2). The resulting excess CNS serotonin acts on serotonin receptors and produces the clinical effects. The exact role of the various serotonin receptors is not completely clear, but there is good evidence that the severe life-threatening clinical effects, such as rigidity and hyperthermia, are mediated by the 5-HT2A receptors.

Serotonin toxicity is sometimes called the serotonin syndrome, which is often used to refer to clinical effects “as defined by the Sternbach criteria.” However, these criteria were stated to be provisional, are non-specific and have never been validated (see Diagnosis of serotonin toxicity). The clinical features reported in the original description of the serotonin syndrome by Sternbach have often been taken as diagnostic criteria, which has led to some reported associations with medications that clearly do not cause serotonin excess. The atypical antipsychotic drugs, such as olanzapine, are a striking example. These have been reported as causing the serotonin syndrome, despite having antiserotonergic actions. We contend that the diagnostic criteria developed more recently by our group — the Hunter Serotonin Toxicity Criteria — are much more specific for serotonin toxicity.

Clinical features of serotonin toxicity
Serotonin toxicity is characterised by the presence of a triad of clinical features: neuromuscular excitation, autonomic stimulation, and changes in mental state (Box 3). There are a number of specific neurological signs that are not seen in many other conditions that should direct the clinician towards a diagnosis of serotonin toxicity. The most important is generalised hyperreflexia. Sustained clonus is usually found at the ankle; ocular clonus (or non-directional nystagmus) is also very common. Generalised spontaneous clonus may occur in moderate-to-severe cases, and is seen rarely in any condition other than serotonin toxicity. The lower limbs usually have a much greater degree of hyperreflexia and clonus than the upper limbs (although a mechanism for this consistent observation is not known).

Some mental state and autonomic features are also nearly always present, but have lower diagnostic utility, as they are indistinguishable from those observed with other causes of an agitated delirium. However, the presence of these features is often associated with moderate-to-severe serotonin toxicity.

Assessment of serotonin toxicity: diagnosis and severity
The assessment of serotonin toxicity requires determining, first, whether the clinical features are consistent with serotonin toxicity and, second, the severity of the toxicity. In patients with suspected serotonin toxicity, the clinical assessment should include observation for tremor, myoclonic jerks, diaphoresis, ocular clonus and
agitation. Vital signs (heart rate, blood pressure and temperature) will usually be sufficient to diagnose autonomic features. However, most important is a focused neurological examination — mental state (eg, orientation, concentration, short-term memory); upper- and lower-limb tone, clonus and reflexes; and pupillary size, reaction and extraocular movements (opcosclonus). In most cases this is sufficient to make a confident diagnosis.2

Diagnosis of serotonin toxicity

A number of diagnostic criteria have been suggested for serotonin toxicity. The first and most commonly used are Sternbach’s criteria.6 Many of the 10 clinical features suggested as typical of serotonin toxicity by Sternbach are non-specific. These would also be commonly observed in many other conditions such as anticholinergic delirium, and alcohol and drug withdrawal states.2

Sternbach’s clinical definition was based on case reports and small published case series. Sternbach recognised that the features were non-specific and specified that other possible causes of the features must be excluded. Unfortunately, this caveat on the original description is almost routinely ignored. Thus, while Sternbach’s criteria remain useful for early recognition, they cannot by definition be used in differential diagnosis.1

As the clinical features of Sternbach’s criteria are not specific, they are also not useful for identifying new drugs as a cause of serotonin toxicity. Again, by definition they state that a known serotonergic drug must have been recently added or increased in dose. The HSTC can be used to determine whether a patient who has taken an overdose has significant serotonin toxicity (Box 4).2

As the HSTC were validated in the setting of a toxicology service where other drug-induced syndromes are frequent, the criteria are much more specific than Sternbach’s criteria for features that solely relate to serotonin toxicity. Because they are more specific, the HSTC can be used for adverse drug reactions, but have not been validated for this purpose.

Differential diagnosis

Although other adverse drug reactions can be initially mistaken for serotonin toxicity, a careful examination for specific neurological features, such as clonus, hyperreflexia and tone, makes it possible to distinguish other conditions. A list of differential diagnoses is given in Box 5. The most commonly confused neurotoxic syndrome is the neuroleptic malignant syndrome. However, neuroleptic malignant syndrome is associated with bradykinesia, lead pipe rigidity, and other extrapyramidal features, in contrast to the hyperkinesia, hyperreflexia and clonus seen with serotonin toxic-

3 Clinical features of serotonin toxicity

<table>
<thead>
<tr>
<th>Neuromuscular effects</th>
<th>Autonomic effects</th>
<th>Mental state changes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hyperreflexia</td>
<td>Hyperthermia: mild, &lt; 38.5°C; severe ≥ 38.5°C</td>
<td>Agitation</td>
</tr>
<tr>
<td>Clonus</td>
<td>Tachycardia</td>
<td>Hypomania</td>
</tr>
<tr>
<td>Myoclonus</td>
<td>Diaphoresis</td>
<td>Anxiety</td>
</tr>
<tr>
<td>Shivering</td>
<td>Hypertonia/rigidity</td>
<td>Confusion</td>
</tr>
<tr>
<td>Tremor</td>
<td>Flushing</td>
<td>Mydriasis</td>
</tr>
</tbody>
</table>
The spectrum of serotonin toxicity can be roughly divided into three groups of severity based on the requirement for medical intervention:

- **Mild serotonergic features.** These may or may not interfere with the patient and may occur with therapeutic use of many serotonergic agents.

- **Moderate toxicity.** Symptoms cause the patient significant distress and deserve symptomatic treatment.

- **Severe serotonin toxicity or serotonin crisis.** This is characterised by a rapidly increasing temperature associated with muscle rigidity, and will progress to multiorgan failure if not treated within hours. This is a medical emergency and is almost exclusively associated with combinations of drugs acting at different sites, most commonly including a monoamine oxidase inhibitor and an SSRI.

A similar division was also suggested by Radomski and colleagues, labelled as mild serotonin toxicity, serotonin syndrome, and toxic states. A number of other scoring systems have been suggested; for example, a serotonin toxicity scale devised by Hegel and coworkers for depressed patients taking paroxetine.

Serotonin toxicity occurs in three main settings. Adverse reactions to normal therapeutic doses usually only cause mild-to-moderate toxicity. Overdose of a single serotonergic agent typically leads to moderate toxicity only. Nearly all severe serotonin toxicity relates to drug interactions (which may also occur in overdose).

There are a number of different mechanisms by which the drugs associated with serotonin toxicity (Box 1) cause excess serotonin. As mentioned above, severe serotonin toxicity mostly occurs with combinations of drugs (most commonly an SSRI and a monoamine oxidase inhibitor) acting at different sites. Patients who ingest any combination of serotonergic drugs in overdose must be observed carefully. However, not all combinations cause increased toxicity. For example, although methylenedioxymethamphetamine (MDMA; ecstasy) can cause serotonin toxicity, SSRIs do not appear to increase serotonergic effects from such serotonergic amphetamines and may reduce neurotoxicity.

That single agents are unlikely to cause severe serotonin toxicity has been confirmed in studies of overdose patients ingesting SSRIs alone. In one study of SSRI overdoses, serotonin toxicity occurred in 15% of cases, but there were no severe cases.

**Treatment**

Treatment for all forms of serotonin toxicity is supportive care and cessation of any serotonergic medications. Severe serotonin toxicity or serotonin crisis is a medical emergency and initial manage-

---

**5 Differential diagnoses for serotonin toxicity**

<table>
<thead>
<tr>
<th>Differential diagnosis</th>
<th>Distinguishing features</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuroleptic malignant syndrome</td>
<td>Absence of neuromuscular excitation,* and presence of bradykinesia, lead-pipe rigidity, and extrapyramidal features</td>
</tr>
<tr>
<td>Non-convulsive seizures</td>
<td>Electroencephalogram features, and response to benzodiazepines</td>
</tr>
<tr>
<td>Acute baclofen withdrawal</td>
<td>History of intrathecal baclofen pump, and response to baclofen</td>
</tr>
<tr>
<td>CNS infection — encephalitis, meningitis</td>
<td>Absence of neuromuscular excitation*</td>
</tr>
<tr>
<td>Anticholinergic delirium</td>
<td>Absence of neuromuscular excitation,* bowel sounds absent, and dry skin</td>
</tr>
<tr>
<td>Sympathomimetic toxicity</td>
<td>Absence of neuromuscular excitation*</td>
</tr>
<tr>
<td>Malignant hyperthermia</td>
<td>Anaesthetic exposure, and absence of neuromuscular excitation*</td>
</tr>
</tbody>
</table>

* Hyperreflexia, clonus and myoclonus

CNS = central nervous system.
ment must focus on airway, breathing and circulation. Supportive care, including passive and active cooling of the patient, sedation, intubation and muscle paralysis, must take precedence over any specific pharmacological treatment. Hyperthermia and muscle rigidity appear to be the most important effects, and this supportive care can prevent secondary complications, such as rhabdomyolysis, renal failure and disseminated intravascular coagulation.

Serotonin toxicity may progressively increase over a number of hours after ingestion of implicated drugs. Patients who have moderate serotonin toxicity should be observed for a period of 6 hours; however, if a slow-release formulation has been ingested, such as venlafaxine, observation should be continued for 12 hours. It is appropriate to provide symptomatic treatment for these patients, including benzodiazepine sedatives, antiepileptics and specific pharmacological therapy. Most patients will improve within 24 hours of ceasing the serotonergic medication.

There may be a role for specific serotonin antagonists in serotonin toxicity, and animal studies provide data that non-specific HT3-antagonists and more selective 5-HT2A-antagonists reverse the lethal effects of serotonin toxicity. However, it is difficult to separate these “responses” from the natural resolution of toxicity. There are no controlled trials demonstrating their effectiveness and further study is required. Cyproheptadine and chlorpromazine are the HT2-antagonists that have been used most extensively, and have a long history of safe use for other medical conditions. Oral cyproheptadine (4–12 mg) is probably the most useful 5-HT2 antagonist for moderate toxicity. Its main side effect is sedation, which is usually beneficial. However, as cyproheptadine can only be administered orally, it is unlikely to be effective in patients administered activated charcoal, and has limited use in severe toxicity. In severe serotonin toxicity, chlorpromazine may be more appropriate to use for sedation than other routine sedative agents. It can cause hypotension, so patients must receive sufficient volume loading. Other non-selective 5-HT2 antagonists, such as the atypical antipsychotics, may be effective, but there is far less experience with their use.

In patients who ingest overdoses of serotonergic agents, there are a few additional considerations. The selective use of activated charcoal may be warranted, but only if it can be given within an hour. Early risk assessment should also consider the possibility of interacting drugs, and non-serotonergic toxic effects (e.g. QT prolongation with citalopram).

Some individuals appear to be more susceptible to mild-to-moderate serotonin toxicity, but it is unclear whether this usually has a pharmacokinetic (e.g. decreased drug metabolism) or pharmacodynamic (e.g. serotonin receptor polymorphism) explanation. A great deal of research would be needed to enable identification of such individuals before treatment. Until then, prevention of serotonin toxicity is as simple (or as difficult) as avoiding prescribing serotonergic drugs. However, we believe that avoiding monoamine oxidase inhibitors may be sufficient to prevent life-threatening toxicity. It also makes sense to us to generally minimise the use of serotonergic drugs used for non-psychiatric conditions.

Competing interests
None identified.

Author details
Geoffrey K Isbister, MB BS, MD, FACEM, Senior Research Fellow, and Clinical Toxicologist1,2,3
Nicholas A Buckley, BMed, MD, FRACP, Clinical Pharmacologist, and Associate Professor4
Ian M Whyte, MB BS, FRACP, Senior Staff Specialist, and Conjoint Professor2,3
1 Tropical Toxinology Unit, Menzies School of Health Research, Charles Darwin University, Darwin, NT.
2 Department of Clinical Toxicology and Pharmacology, Calvary Mater Newcastle Hospital, and University of Newcastle, Newcastle, NSW.
3 Discipline of Clinical Pharmacology and Toxicology, University of Newcastle, Newcastle, NSW.
4 Department of Clinical Pharmacology and Toxicology, Canberra Hospital, and Australian National University, Canberra, ACT.
Correspondence: gsbite@ferntree.com

References
18 Malberg JE, Sabol KE, Seiden LS. Co-administration of MDMA with drugs that protect against MDMA neurotoxicity produces different effects on body temperature in the rat. J Pharmacol Exp Ther 1996; 278: 258-267.
19 Sanchez V, Camarero J, Esteban B, et al. The mechanisms involved in the long-lasting neuroprotective effect of fluoxetine against MDMA...
CLINICAL UPDATE


(Received 29 Mar 2007, accepted 25 Jun 2007)